Otsuka Holdings Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Otsuka Holdings Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the Otsuka Holdings Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Otsuka Holdings Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Otsuka Holdings Co., Ltd.

The report provides overview of Otsuka Holdings Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Otsuka Holdings Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Otsuka Holdings Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Otsuka Holdings Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Otsuka Holdings Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Otsuka Holdings Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Otsuka Holdings Co., Ltd. Snapshot 7

Otsuka Holdings Co., Ltd. Overview 7

Key Information 7

Key Facts 7

Otsuka Holdings Co., Ltd. - Research and Development Overview 8

Key Therapeutic Areas 8

Otsuka Holdings Co., Ltd. - Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products - Monotherapy 13

Pipeline Products - Combination Treatment Modalities 14

Pipeline Products - Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Otsuka Holdings Co., Ltd. - Pipeline Products Glance 17

Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Phase III Products/Combination Treatment Modalities 18

Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products 19

Phase II Products/Combination Treatment Modalities 19

Phase I Products/Combination Treatment Modalities 20

Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products 21

Preclinical Products/Combination Treatment Modalities 21

Otsuka Holdings Co., Ltd. - Drug Profiles 22

(carteolol hydrochloride + latanoprost) 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

(tipiracil hydrochloride + trifluridine) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

levetiracetam 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ponatinib hydrochloride 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

tolvaptan 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

(aripiprazole + sertraline) 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

(gimeracil + oteracil + tegafur) 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

aripiprazole ER 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

AVP-786 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

brexpiprazole 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

delamanid 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

nabiximols 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

rebamipide 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

(dextromethorphan + quinidine sulfate) 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

OCV-501 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

OPA-15406 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

OPS-2071 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

probucol 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

tetomilast 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

OPA-6566 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

OPB-111001 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

LPC-01 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

LUAF-20513 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

OCVC-02 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

OPB-111077 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

OPC-108459 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

OPC-39436 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

OPC-64005 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

OPC-28326 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Otsuka Holdings Co., Ltd. - Pipeline Analysis 71

Otsuka Holdings Co., Ltd. - Pipeline Products by Target 71

Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration 73

Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type 74

Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action 75

Otsuka Holdings Co., Ltd. - Recent Pipeline Updates 77

Otsuka Holdings Co., Ltd. - Dormant Projects 113

Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products 114

Discontinued Pipeline Product Profiles 114

(gimeracil + oteracil + tegafur) 114

(tipiracil hydrochloride + trifluridine) 114

AVP-13358 114

AZD-2479 115

brexpiprazole 115

dasatinib 115

OCV-101 115

OPB-31121 115

OPB-51602 115

rebamipide 115

Otsuka Holdings Co., Ltd. - Company Statement 117

Otsuka Holdings Co., Ltd. - Locations And Subsidiaries 118

Head Office 118

Other Locations & Subsidiaries 118

Appendix 121

Methodology 121

Coverage 121

Secondary Research 121

Primary Research 121

Expert Panel Validation 121

Contact Us 121

Disclaimer 122

List of Tables

List of Tables

Otsuka Holdings Co., Ltd., Key Information 7

Otsuka Holdings Co., Ltd., Key Facts 7

Otsuka Holdings Co., Ltd. – Pipeline by Indication, 2016 9

Otsuka Holdings Co., Ltd. – Pipeline by Stage of Development, 2016 12

Otsuka Holdings Co., Ltd. – Monotherapy Products in Pipeline, 2016 13

Otsuka Holdings Co., Ltd. – Combination Treatment Modalities in Pipeline, 2016 14

Otsuka Holdings Co., Ltd. – Partnered Products in Pipeline, 2016 15

Otsuka Holdings Co., Ltd. – Partnered Products/ Combination Treatment Modalities, 2016 16

Otsuka Holdings Co., Ltd. – Pre-Registration, 2016 17

Otsuka Holdings Co., Ltd. – Phase III, 2016 18

Otsuka Holdings Co., Ltd. – Phase II, 2016 19

Otsuka Holdings Co., Ltd. – Phase I, 2016 20

Otsuka Holdings Co., Ltd. – Preclinical, 2016 21

Otsuka Holdings Co., Ltd. – Pipeline by Target, 2016 71

Otsuka Holdings Co., Ltd. – Pipeline by Route of Administration, 2016 73

Otsuka Holdings Co., Ltd. – Pipeline by Molecule Type, 2016 74

Otsuka Holdings Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 75

Otsuka Holdings Co., Ltd. – Recent Pipeline Updates, 2016 77

Otsuka Holdings Co., Ltd. – Dormant Developmental Projects,2016 113

Otsuka Holdings Co., Ltd. – Discontinued Pipeline Products, 2016 114

Otsuka Holdings Co., Ltd., Other Locations 118

Otsuka Holdings Co., Ltd., Subsidiaries 118

List of Figures

List of Figures

Otsuka Holdings Co., Ltd. – Pipeline by Top 10 Indication, 2016 9

Otsuka Holdings Co., Ltd. – Pipeline by Stage of Development, 2016 12

Otsuka Holdings Co., Ltd. – Monotherapy Products in Pipeline, 2016 13

Otsuka Holdings Co., Ltd. – Combination Treatment Modalities in Pipeline, 2016 14

Otsuka Holdings Co., Ltd. – Partnered Products in Pipeline, 2016 15

Otsuka Holdings Co., Ltd. – Pipeline by Top 10 Target, 2016 71

Otsuka Holdings Co., Ltd. – Pipeline by Route of Administration, 2016 73

Otsuka Holdings Co., Ltd. – Pipeline by Molecule Type, 2016 74

Otsuka Holdings Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 75

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports